Suppression of FoxO1 mRNA by β2-adrenoceptor–cAMP signaling through miR-374b-5p and miR-7a-1-3p in C2C12 myotubes

Saki Shimamoto1,2,3, Kazuki Nakashima4, Nao Nishikoba1, Rukana Kohrogi1, Akira Ohtsuka1,2, Shinobu Fujimura3 and Daichi Ijiri1,2

1 Department of Agricultural Sciences and Natural Resources, Kagoshima University, Japan
2 The United Graduate School of Agricultural Sciences, Kagoshima University, Japan
3 Graduate School of Science and Technology, Niigata University, Japan
4 Division of Meat Animal and Poultry Research, Institute of Livestock and Grassland Science, NARO, Tsukuba, Japan

Keywords
FoxO; microRNA; skeletal muscle; ubiquitin ligase; β2-adrenoceptor

Correspondence
D. Ijiri, Department of Agricultural Sciences and Natural Resources, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan
Fax: +81 99 285 8654
Tel.: +81 99 285 8652
E-mail: ijiri@agri.kagoshima-u.ac.jp

(Received 8 November 2021, revised 21 December 2021, accepted 13 January 2022)
doi:10.1002/2211-5463.13368

Edited by Jan Krützfeldt

β2-Adrenoceptor (β2-AR) signaling decreases the transcriptional activity of forkhead box O (FoxO), but the underlying mechanisms remain incompletely understood. Here, we investigated how β2-AR signaling regulates the protein abundance of FoxO and its transcriptional activity in skeletal muscle. We observed that stimulation of β2-AR with its selective agonist, clenbuterol, rapidly decreased FoxO1 mRNA expression, and this was accompanied by a decrease in either FoxO1 protein level or FoxO transcriptional activity. We subsequently observed that miR-374b-5p and miR-7a-1-3p were rapidly upregulated in response to β2-AR stimulation. Transfection with mimics of either miRNA successfully decreased FoxO1 mRNA. Moreover, because β2-AR stimulation increased cAMP concentration, pretreatment with an adenylyl cyclase inhibitor canceled out these effects of β2-AR stimulation. These results suggest that β2-AR stimulation results in rapid upregulation of miR-374b-5p and miR-7a-1-3p in myotubes, which in turn results in a decrease in FoxO1 mRNA expression via the β2-AR–cAMP signaling pathway.

Skeletal muscle mass is controlled through a delicate balance between protein synthesis and protein degradation [1]. Changes in the rate of protein degradation may contribute to either normal muscle growth or muscle atrophy [2,3]. In addition, the rate of protein degradation is probably regulated through the ubiquitin (Ub)–proteasome system [4–6]. In this system, proteins destined for degradation are covalently linked to a chain of Ub molecules, which marks them for breakdown by the 26S proteasome [7,8]. Because the mRNA expression of Ub ligases clearly correlates with polyubiquitination, they play an important role in controlling polyubiquitination, a rate-limiting step in the Ub–proteasome system [7,9,10].

The forkhead box O (FoxO) transcription factors have a critical role in the transcriptional regulation of Atrogin-1/MAFbx, one of the muscle-specific Ub ligases, and thus, they play an important role in controlling the degradation of muscle protein [11]. The transcriptional activity of FoxO proteins is also

Abbreviations
3′UTR, 3′ untranslated region; cAMP, cyclic adenosine monophosphate; DMEM, Dulbecco’s modified Eagle’s medium; FoxO, forkhead box O; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HuR, RNA-binding protein Elav/Hu; miRNA, microRNA; P/S, penicillin/streptomycin; PBS, phosphate-buffered saline; PKA, protein kinase A; QKI, RNA-binding protein Quaking; SE, standard error; Ub, ubiquitin; β2-AR, β2-adrenoceptor.
affected by a variety of post-translational modifications (e.g., phosphorylation, acetylation, and monoubiquitination) [12,13]. Phosphorylation of FoxO protein changes its subcellular localization from the nucleus to the cytosol, decreases its DNA binding activity, and thereby suppresses its transcriptional activity [13,14]. It is well known that the insulin and insulin-like growth factor-1/AKT pathway suppresses FoxO transcriptional activity and thereby decreases its transcriptional activity [15–19].

In skeletal muscle, either epinephrine or norepinephrine decreases the rate of ubiquitin–proteasome system-dependent protein degradation by reducing the expression of Atrogin-1/MAFbx mRNA [20,21]. Three β-adrenergic receptor (β-AR) subtypes have been identified, β1-AR, β2-AR, and β3-AR, and the injection of β2-AR agonists (e.g., clenbuterol, terbutaline, and formoterol) also reduces the gene expression of Atrogin-1/MAFbx, consequently exerting an anabolic effect [22,23]. Our previous study suggested that a β2-AR selective agonist, clenbuterol, suppressed the transcriptional activity of FoxO by AKT-mediated phosphorylation [24]. Recently, the injection of norepinephrine was shown to suppress FoxO transcriptional activity via the cAMP-protein kinase A (PKA) pathway, consequently decreasing the expression of Atrogin-1/MAFbx mRNA in murine skeletal muscles [23]. Interestingly, Silveria et al. [25] also reported that norepinephrine stimulates FoxO phosphorylation and decreases FoxO protein abundance. The abundance of FoxO protein also has dramatic effects on its own transcriptional activity and/or the functions of its downstream targets [26,27]. These findings raised the possibility that either β2-AR agonists or norepinephrine regulates FoxO1 transcriptional activity by controlling not only phosphorylation level but also protein abundance in skeletal muscle. However, the mechanisms behind the adrenergic signaling-induced downregulation of FoxO protein abundance in skeletal muscle remain unclear.

On the basis of these findings, to elucidate the role of FoxO in controlling β2-AR-induced suppression of muscle protein degradation, this study investigated how β2-AR signaling regulates the protein abundance of FoxO and its transcriptional activity in skeletal muscle.

Materials and methods

Cell cultures

Murine myoblasts (C2C12, ATCC® CRL-1772™) were purchased from ATCC (Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (P/S) for 3 days. Cells were grown in 10 cm dish (for measurement of N'-methylhistidine release and protein content) or 6-well plate (for all other experiments) at 37 °C in 5% (v/v) CO2 in a humidified environment. To induce myotube formation, the medium was replaced with DMEM supplemented with 2% horse serum and 1% P/S for 5 days. All drugs were made up in phosphate-buffered saline (PBS) and subsequently added to the appropriate tissue culture wells (1 : 1000). The vehicle-control wells received just PBS in the same volume as the treatment groups. To study the effects of β2-AR agonist treatment, C2C12 myotubes were treated with clenbuterol (1 μM), because this concentration of clenbuterol has been reported to successfully decrease Atrogin-1/MAFbx mRNA expression in C2C12 myotubes [28]. In addition, an inhibitor of adenyl cyclase (SQ22536, 10 μM) was used to block cAMP synthesis.

RNA extraction and quantitative real-time polymerase chain reaction (PCR)

C2C12 myotubes were homogenized in ISOGEN II (Nippon Gene, Tokyo, Japan), in accordance with the manufacturer’s instructions. Real-time PCR was performed as described previously [24]. Each sample was run in duplicate with no template or negative RT controls in each plate. Efficiencies and R² were assessed using five-point cDNA serial dilution: PCRs were highly specific and reproducible (0.96 < R² < 1.05) and all primer pairs had equivalent PCR efficiency (from 98% to 105%). The melting curves revealed a single peak for all primer pairs. The coefficient of variation was 7–11%. Amplification, dissociation curves, and gene expression analysis were performed using the Dissociation Curves software (Applied Biosystems, Foster City, CA, USA). The level of 18S ribosomal RNA was used as an internal standard. The primers used in this study are listed in Table 1. Each gene expression result is expressed as the ratio of the experimental treatment value to the corresponding untreated control value.

Antibodies

Anti-FoxO1 (#9454) and anti-phospho-FoxO1 (Ser256, #9461) were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH, sc-20357), anti-rabbit IgG (sc-2030), and anti-goat IgG (sc-2020) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Protein extraction and western blot analysis

C2C12 myotubes were homogenized in 500 μL of a lysis buffer consisting of 50 mM Tris, 150 mM NaCl, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM ethylenediaminetetraacetic acid, and 1% protease inhibitor cocktail (25955-11; Nacalai Tesque, Kyoto, Japan), pH 8.0. The lysate was centrifuged at 20,000 g for 10 min at 4 °C, and the supernatant was collected.

Western blot analysis was performed as described previously [24]. In brief, samples were electrophoresed on an SDS/10% (w/v) polyacrylamide gel and then transferred to a polyvinylidene difluoride membrane (IPVH00010; Millipore Co., Billerica, MA, USA). The membrane was blocked with Bullet Blocking One (13779-01; Nacalai Tesque) for 10 min at room temperature. Subsequently, the blocked membrane was incubated with primary antibody in Can Get Signal I (Toyobo, Osaka, Japan) overnight at 4 °C (1:5000 dilution). Then, these membranes were incubated with a secondary antibody in Can Get Signal II at 37 °C for 2 h (1:5000 dilution). The blots were detected using Western Blotting Detection Reagent (ATTO Co., Tokyo, Japan), in accordance with the manufacturer’s instructions. Next, all membranes were incubated with primary antibody against GAPDH in Can Get Signal I overnight at 4 °C (1:5000 dilution). Then, these membranes were incubated with a secondary antibody against goat IgG in Can Get Signal II at 37 °C for 2 h (1:5000 dilution). The blots were detected using the Western Blotting Detection Reagent. Relative band intensity was quantified using IMAGEJ software (National Institutes of Health, Bethesda, MD, USA).

Luciferase assay
C2C12 myotubes were transfected with the FoxO reporter and negative control reporter (60964; BPS Bioscience, San Diego, CA, USA) using the TransIT-X2 Dynamic Delivery System. Fold induction of normalized reporter activity by FoxO (ratio of normalized reporter activity in the presence of clenbuterol to that in the presence of the negative control expression vector) in C2C12 myotube culture medium after 3 h of clenbuterol stimulation was calculated. The myotubes were also transfected with miRNA mimic (negative control, miR-374b-5p, or miR-7a-1-3p). At 24 h post-transfection, luciferase activity was measured with the Dual-Glo® Luciferase Assay System (Promega, Madison, WI, USA) and normalized to the internal control.

Measurement of N’-methylhistidine release in the medium of C2C12 myotubes
C2C12 myotubes were incubated with clenbuterol (1 μM) for 24 h in DMEM. The medium was then collected, and N’-methylhistidine concentration was determined as described previously [29]. Culture medium was mixed with 20% sulfosalicylic acid and centrifuged at 10,000 g for 5 min. The supernatant was recovered and evaporated under reduced pressure. The residue was dissolved in 0.2 M pyridine and applied to a cation-exchange column (7 × 60 mm, Dowex 50W-X8, 200–400 mesh, pyridine form). After most of the acidic and neutral amino acid had been washed out with 0.2 M pyridine, N’-methylhistidine was eluted with 1 M pyridine and collected. The solvent was evaporated, and the residue was dissolved in mobile phase (15 mM sodium 1-octanesulfonate in 20 mM KH2PO4). An aliquot was injected into an HPLC system (LC-2000 Plus HPLC System; JASCO Co., Ltd., Tokyo, Japan) equipped with an Inertsil ODS-80A column (4.6 × 250 mm, 5 μm; GL Sciences, Tokyo, Japan). The column was attached to an oven at 50 °C. A fluorometric detector set at an excitation wavelength of 365 nm and an emission wavelength of 460 nm was used to monitor the fluorescence derived from the reaction with ortho-phthalaldehyde. The protein content was determined by the Bradford method with bovine serum albumin as a standard [30].

Measurement of protein content of C2C12 myotubes
C2C12 myotubes were incubated with clenbuterol (1 μM) for 24 h in DMEM. Total protein and DNA were simultaneously isolated from myotubes using ISOGEN™ reagent (Nippon Gene), in accordance with the manufacturer’s instructions. The protein content was determined by the Bradford method with bovine serum albumin as a standard [30] and normalized by DNA content, which was determined using the Nanodrop Lite spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) readings at 260 nm.

miRNA extraction, microarray analysis, and miRNA expression
Using the mirVana™ miRNA Isolation Kit (Ambion, Austin, TX, USA), miRNAs were isolated in accordance with the manufacturer’s instructions. All samples were diluted to a final concentration of 3 ng·µL−1. The samples were used immediately or stored at −80 °C until use, and miRNA microarray assays were outsourced to Fillgen Inc. (Nagoya,
Japan). Microarray analysis of miRNAs was performed using the Affymetrix GeneChip® miRNA 4.0 Array (Thermo Fisher Scientific). These arrays were scanned with the GeneChip® Scanner 3000 7G (Thermo Fisher Scientific). Differentially expressed miRNAs were analyzed using the Affymetrix® Expression Console™ Software (Thermo Fisher Scientific).

The miRNAs were reverse transcribed using the Taqman® miRNA reverse transcription kit (Applied Biosystems), and real-time PCR of miRNAs was performed using the TaqMan Universal Master Mix II (Applied Biosystems), in accordance with the manufacturer’s instructions. Quantitative analysis of the expression was carried out using the TaqMan Assay Kit (Applied Biosystems). The level of snoRNA142 was used as an internal standard. The Taqman assay IDs used in this study are as follows: snoRNA142 (Taqman assay ID: 001231), miR-7a-1-3p (Taqman assay ID: 001338), and miR-374b-5p (Taqman assay ID: 001319). Each miRNA expression result is expressed as the ratio of the experimental treatment value to the corresponding untreated control value.

**Transfection with small interfering RNAs**

Transient transfection of C2C12 cells was performed using the TransIT-T2 Dynamic Delivery System (Mirus, Madison, WI, USA), in accordance with the manufacturer’s instructions. Briefly, 30 μM mirVana miRNA mimic (miR-374b-5p, miR-7038-3p, miR-7016-3p, or miR-7a-1-3p) or AccuTarget™ miRNA Mimic Negative Control #1 (4464058, Ambion) was separately used in each transfection. The assay IDs of mirVana miRNA mimics used in this study are as follows: miR-374b-5p (MC11339), miR-7038-3p (MC26508), miR-7016-3p (MC30144), and miR-7a-1-3p (MC10440). After transfection, cells were added to prewarmed medium and immediately placed in an incubator at 37 °C and 5% CO2. Cells were harvested at 24 h after transfection.

**cAMP levels in C2C12 myotubes**

cAMP levels were determined using an Enzyme Immuno Assay Kit (Cayman Chemical, Ann Arbor, MI, USA), in accordance with the manufacturer’s instructions.

**Statistical analysis**

The data are expressed as mean ± standard error (SE). Statistical comparisons were performed using Student’s t-test, Dunnett’s test, or Tukey’s multiple comparison test. P values under 0.05 or 0.01 were considered to indicate statistical significance. These analyses were performed using R software (version 4.1.1, Free Software, https://www.r-project.org).

**Results**

**β2-AR agonist, clenbuterol, reduces protein degradation followed by suppression of FoxO1 mRNA expression in myotubes**

β2-AR activation by 1 μM clenbuterol resulted in decreases of FoxO1 mRNA expression after 1 and 3 h of stimulation (Fig. 1A). In agreement with the decreased mRNA expression, decrease in FoxO1 protein levels was confirmed 3 h after clenbuterol stimulation, while phosphorylated FoxO1 protein levels were increased (Fig. 1B). The transcripational activity of FoxO protein was determined by a luciferase reporter assay, in which the gene for luciferase was under the control of the FoxO-response element. FoxO-specific reporter assays showed that β2-AR activation by 1 μM clenbuterol resulted in decreased FoxO transcriptional activity after 3 h (Fig. 1C). In addition, clenbuterol stimulation significantly decreased the mRNA expression of Atrogin-1/MAFbx, which is a transcriptional target of FoxO1, after 3 h of stimulation (Fig. 1D). Furthermore, the release of N2-methylhistidine, as an index of muscle protein degradation, was decreased in C2C12 myotubes 24 h after clenbuterol stimulation, while the protein concentration of C2C12 myotubes 24 h after clenbuterol stimulation was higher than that of the control myotubes (Fig. 1E,F).

**Profiling miRNA expression changes in response to β2-AR stimulation**

We performed a microarray analysis to identify miRNAs that were differentially expressed between C2C12 myotubes stimulated with 1 μM clenbuterol for 1 h and their control myotubes (GSE130181). We found that 3142 miRNAs were detectable in these myotubes. The differentially expressed miRNAs among them are shown as heat maps in Fig. 2. In total, 103 miRNAs were differentially expressed; 64 miRNAs were upregulated in clenbuterol-stimulated myotubes (Fig. 2A), and 39 were downregulated (Fig. 2B).

**Identification and validation of miRNA interaction sites in the 3' untranslated region (3'UTR) of FoxO1**

We focused on nine miRNAs that were upregulated more than 2.5-fold in clenbuterol-stimulated C2C12 myotubes compared with the levels in controls. We used the prediction algorithm TargetScan to identify miRNAs having candidate binding sites within the 3'UTR of FoxO1. As shown in Fig. 3A, this analysis
predicted that the 3′UTR of FoxO1 might be targeted by four of the nine miRNAs (each having one to three putative binding sites). We therefore focused further on these four miRNAs: miR-374b-5p, miR-7038-3p, miR-7016-3p, and miR-7a-1-3p. To investigate their functional roles, we examined FoxO1 expression in C2C12 myotubes transfected with their mimics. Among them, transfection with the miR-374b-5p and miR-7a-1-3p mimics successfully decreased FoxO1 mRNA expression in the C2C12 myotubes transfected with their mimics. A significant decrease in the relative luciferase activity compared with that of their control myotubes 24 h after transfection (Fig. 3C). In concert with FoxO1 protein levels, transfection with either miR-374b-5p or miR-7a-1-3p mimic decreased Atrogin-1/MAFbx mRNA expression (Fig. 3D).

**The inhibition of cAMP synthesis canceled out β2-AR agonist-induced decrease in FoxO1 mRNA expression**

Clenbuterol stimulation significantly increased the cAMP concentration in C2C12 myotubes after 1 h of stimulation, while this effect was not observed in C2C12 myotubes pretreated with an adenylyl cyclase inhibitor (SQ22536) before clenbuterol stimulation.
Fig. 2. Microarray analysis of miRNA expression in C2C12 myotubes with or without β2-AR stimulation. Overall, 64 miRNAs were upregulated (A) and 39 were downregulated in clenbuterol-stimulated myotubes (B). Blue and red denote lower and higher expression, respectively. miRNAs whose levels changed significantly (P < 0.05) after 1 h of stimulation with the β2-AR agonist clenbuterol are shown (n = 3). CB, clenbuterol; CT, control; β2-AR, β2-adrenoceptor.
In addition, although clenbuterol stimulation increased the expression levels of miR-375b-5p and miR-7a-1-3p, neither of these was observed in C2C12 myotubes pretreated with SQ22536 before clenbuterol stimulation (Fig. 4B).

Clenbuterol stimulation significantly decreased the expression level of FoxO1 mRNA, while this was not observed in C2C12 myotubes pretreated with SQ22536 before clenbuterol stimulation (Fig. 4B).

Clenbuterol stimulation significantly decreased the expression level of FoxO1 mRNA, while this was not observed in C2C12 myotubes pretreated with SQ22536 (Fig. 4C). In concert with this, Atrogin-1/MAFbx mRNA expression was decreased by clenbuterol stimulation, while this was not observed in C2C12 myotubes pretreated with SQ22536 (Fig. 4D).

**Discussion**

The data obtained in this study demonstrate that β2-AR stimulation acutely suppressed FoxO1 mRNA expression and consequently reduced FoxO1 protein abundance in C2C12 myotubes. In addition, β2-AR stimulation also increased the phosphorylation of FoxO1 proteins in the myotubes. These results suggest that β2-AR stimulation suppressed FoxO1 transcriptional activity via the dual mechanisms of altering FoxO1 protein abundance and phosphorylation in skeletal muscles and consequently suppresses muscle protein degradation by decreasing Atrogin-1/MAFbx mRNA expression in skeletal muscle.

It has been reported that the half-life of FoxO1 mRNA was calculated to be 4.9 h in murine cardiomyocytes [31]; however, β2-AR stimulation decreased FoxO1 mRNA 1 h after stimulation in C2C12 myotubes in this study. This raised the possibility that β2-AR activation might destabilize FoxO1 mRNA in C2C12 myotubes. Numerous miRNAs are known to influence the evolution and stability of many mRNAs and to adjust protein output [32]. During the last decade, many miRNAs have been identified as post-transcriptional regulators of FoxO synthesis [33]. In this study, β2-AR activation acutely upregulated 64 miRNAs. Among them, miR-9, miR-21, and miR-222
were previously reported to be involved in the regulation of FoxO1 expression by binding the 3' UTR of FoxO1 mRNA in cancer cells [34–36]. These three upregulated miRNAs might contribute to the β2-AR stimulation-induced decrease in FoxO1 expression in C2C12 myotubes. Furthermore, a different set of four miRNAs (miR-374b-5p, miR-7038-3p, miR-7016-3p, and miR-7a-1-3p) predicted to target the 3' UTR of FoxO1.

To investigate the functional activity of these miRNAs, we examined FoxO1 mRNA expression in myotubes transfected with their mimics. Among the four mimics, either miR-374b-5p or miR-7a-1-3p successfully decreased FoxO1 mRNA expression in the C2C12 myotubes. In addition, we confirmed that the transcriptional activity of FoxO was decreased in the C2C12 myotubes transfected with these two mimics. Indeed, decreased Atrogin-1/MAFbx mRNA expression was confirmed in the C2C12 myotubes transfected with either miR-374b-5p or miR-7a-1-3p mimics. These results suggest that, in addition to the previously reported miRNAs (miR-9, miR-21, and miR-222), either miR-374b-5p or miR-7a-1-3p is rapidly upregulated by β2-AR stimulation and destabilizes FoxO1 mRNA, consequently affecting its transcriptional activity against its target gene (e.g., Atrogin-1/MAFbx) in myotubes. However, TargetScan analysis also predicted that the 3' UTR of Atrogin-1/MAFbx would be targeted by both miRNAs, which raises the possibility that these miRNAs directly destabilize Atrogin-1/MAFbx mRNA, even though β2-AR stimulation did not affect Atrogin-1/MAFbx mRNA expression in myotubes within 1 h after stimulation (data not shown).

As mentioned above, norepinephrine stimulation decreases FoxO1 protein abundance via the cAMP–PKA pathway in murine skeletal muscle [25]. β2-AR couples with the G protein, which activates adenylyl cyclase, catalyzing the formation of cAMP [37]. It has also been reported that β2-AR stimulation by clenbuterol increased the cAMP concentration in rat skeletal muscle [38]. In this study, we confirmed that, in C2C12 myotubes, β2-AR stimulation rapidly increased cAMP concentration. Then, to inhibit the β2-AR agonist-induced increase in cAMP, we employed an adenylyl cyclase inhibitor, SQ22536. Pretreatment with SQ22536 successfully canceled out the β2-AR agonist-induced increases in miR-374b-5p and miR-7a-1-3p expression, in concert with the increase of cAMP concentration in C2C12 myotubes. In addition, pretreatment with SQ22536 also canceled out the β2-AR
stimulation-induced decreases in FoxO1 mRNA expression in C2C12 myotubes. Silveira et al. [25] reported that the in vivo muscle-specific activation of PKA, a cAMP-dependent protein kinase, inhibited FoxO transcriptional activity. These results suggest that β2-AR stimulation induced either miR-374b-5p or miR-7a-1-3p via β2-AR–cAMP signaling and that these increased miRNAs in turn contributed to suppressing FoxO1 transcriptional activity in C2C12 myotubes.

It has been reported that cAMP elevation changed the expression of a large number of miRNAs. For example, in human placental cells, forskolin, an inducer of intracellular cAMP, significantly changed the expression of 116 miRNAs [39–41]. However, how β2-AR–cAMP signaling increases either miR-374b-5p or miR-7a-1-3p expression in C2C12 myotubes remains unclear. One possible explanation for this might involve the endoribonucleases (e.g., DICER and DROSHA) required for miRNA processing [42]. In isolated human endometrial stromal cells (hESCs), cAMP and medroxyprogesterone acetate treatment significantly increased DICER expression, suggesting that cAMP elevation was related to the miRNA maturation and degradation of miRNAs [43]. Furthermore, miR-374b-5p and miR-7a-1-3p are involved in Ftx transcript (ENSMUSG00000086370) and heterogeneous nuclear ribonucleoprotein K (ENSMUSG00000021546) (Hnrnpk), respectively. Although the relationship between β2-AR stimulation and Ftx transcript expression remains unclear, it has been reported that β2-AR stimulation increased Hnrnpk protein levels in the skeletal muscle of human with high-intensity training [44]. It was suggested that expressions of these transcripts have important implications for the intensity training [44]. It was suggested that expressions of these transcripts have important implications for the intensity training [44].

In conclusion, β2-AR stimulation by clenbuterol rapidly upregulated miR-374b-5p and miR-7a-1-3p in myotubes and then decreased the mRNA expression of FoxO1 via the β2-AR–cAMP signaling pathway. β2-AR–cAMP signaling suppresses FoxO1 transcriptional activity that would otherwise promote the expression of genes encoding Atrogin-1/MAFbx mRNA, and consequently suppresses protein degradation via the dual mechanisms of altering FoxO1 protein abundance and phosphorylation in skeletal muscles.

Acknowledgements

We thank Dr Manabu Ozawa for technical information and general advice. We also thank Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript. This study was supported by a Grant-in-Aid for Young Scientists (B) (No. 16K18784) and a Grant-in-Aid for JSPS Research Fellows (No. 17J02494) from The Japan Society for the Promotion of Science, to DI and SS, respectively.

Conflict of interest

The authors declare no conflict of interest.

Data accessibility

The data that support the findings of this study are openly available in NCBI’s Gene Expression Omnibus and are accessible through https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi. GEO Series accession number is GSE130181.

Author contributions

SS, KN, AO, and DI conceived and designed the experiments. SS, KN, NN, and RK performed the experiments and contributed reagents/materials/analysis tools. SS, KN, and DI wrote the paper. AO and SF reviewed and revised the paper.

References

1. Russell AP. Molecular regulation of skeletal muscle mass. Clin Exp Pharmacol Physiol. 2010;37:378–84.
2. Goldspink DF. The effects of denervation on protein turnover of rat skeletal muscle. Biochem J. 1976;156:71–80.
3. Goldspink DF, Goldspink G. Age-related changes in protein turnover and ribonucleic acid of the diaphragm muscle of normal and dystrophic hamsters. Biochem J. 1977;162:191–4.
4. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care. 2001;4:183–90.
5. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2004;18:39–51.
6. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol. 2006;17:1807–19.
7. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 1998;17:7151–60.
8. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–79.
Control of FoxO1 mRNA expression by microRNAs

S. Shimamoto et al.  

9 Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704–8.

10 Sachek JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 2004;287:E591–601.

11 Kops GJ, de Ruiter ND, De Vriirs-Smits AM, Powell DR, Bos JL, Burgering BM. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature. 1999;398:630–4.

12 Calnan DR, Brunet A. The FoxO code. Oncogene. 2008;27:2276–88.

13 Daitoku H, Sakamaki J, Fukamizu A. Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta. 2011;1813:1954–60.

14 Biggs WH 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA. 1999;96:7421–6.

15 Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci USA. 2003;100:11285–90.

16 Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117:399–412.

17 Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, et al. The IGF-1/Pi3K/Akt pathway prevents expression of muscle protein-activated ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 2004;14:395–403.

18 Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem. 2005;280:20814–23.

19 Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem. 2005;280:2737–44.

20 Frier BC, Wan Z, Williams DB, Stefansson AL, Wright DC. Epinephrine and AICAR-induced PGC-1α mRNA expression is intact in skeletal muscle from rats fed a high-fat diet. Am J Physiol Cell Physiol. 2012;302:C1772–9.

21 Silveira WA, Gonçalves DA, Graça FA, Andrade-Lopes AL, Bergantin LB, Zanon NM, et al. (2014) Activating AMP/PKA signaling in skeletal muscle suppresses the ubiquitin-proteasome-dependent proteolysis: implications for sympathetic regulation. J Appl Physiol. 1985;117:11–9.

22 Koopman R, Gehrig SM, Léger B, Trieu J, Walrand S, Murphy KT, et al. Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and breakdown during chronic β-adrenoreceptor stimulation in mice. J Physiol. 2010;588:4811–23.

23 Ijiri D, Ishitani K, Shimamoto S, Ishimaru Y, Ohtsuka A. The effects of intraperitoneal clenbuterol injection on protein degradation and myostatin expression differ between the sarctorius and pectoral muscles of neonatal chicks. Gen Comp Endocrinol. 2014;206:111–7.

24 Shimamoto S, Ijiri D, Nakashima K, Kawaguchi M, Ishimaru Y, Furukawa A, et al. Clenbuterol changes phosphorylated FOXO1 localization and decreases protein degradation in the sarctorius muscle of neonatal chicks. Biosci Biotechnol Biochem. 2016;80:1499–504.

25 Silveira WA, Gonçalves DA, Machado J, Lautherbach N, Lustrino D, Paula-Gomes S, et al. cAMP-dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice. FASEB J. 2020;34:12946–62.

26 Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type 1 (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem. 2004;279:41114–23.

27 Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128:309–23.

28 Wannenes F, Magni L, Bonini M, Dimaro I, Caporossi D, Moretti C, et al. In vitro effects of Beta-2 agonists on skeletal muscle differentiation, hypertrophy, and atrophy. World Allergy Organ J. 2012;5:66–72.

29 Kamizono T, Ohtsuka A, Hashimoto F, Hayashi K. Dibutoxybutane suppresses protein degradation and promotes growth in cultured chicken muscle cells. J Poul Sci. 2013;50:37–43.

30 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.

31 Guo W, Jiang T, Lian C, Wang H, Zheng Q, Ma H. QKI deficiency promotes FoxO1 mediated nitrosative stress and endoplasmic reticulum stress contributing to increased vulnerability to ischemic injury in diabetic heart. J Mol Cell Cardiol. 2014;75:131–40.

32 Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature. 2008;455:64–71.

33 Urbánek P, Klotz LO. Posttranscriptional regulation of FOXO expression: microRNAs and beyond. Br J Pharmacol. 2017;174:1514–32.
34 Myatt SS, Wang J, Monteiro LJ, Christian M, Ho K, Fusi L, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 2010; 70:367–77.

35 Go H, Jang J, Kim P, Kim Y, Nam SJ, Paik JH, et al. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget. 2015; 20:15035–49.

36 Shen H, Wang D, Li L, Yang S, Chen X, Zhou S, et al. MiR-222 promotes drug-resistance of breast cancer cells to Adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene. 2017; 596:110–8.

37 McGraw DW, Liggett SB. Molecular mechanisms of β2-adrenergic receptor function and regulation. Proc Am Thorac Soc. 2005; 2:292–6.

38 Ohnuki Y, Umeki D, Mototani Y, Shiozawa K, Nariyama M, Ito A, et al. Role of phosphodiesterase 4 expression in the Epac1 signaling-dependent skeletal muscle hypertrophic action of clenbuterol. Physiol Rep. 2016; 4:e12791.

39 Mori M, Nakagami H, Rodriguez-Araujo G, Nimura K, Kaneda Y. Essential role for miR-196a in brown adipogenesis of white fat progenitor cells. PLoS Biol. 2012; 10:e1001314.

40 Sontakke SD, Mohammed BT, McNeilly AS, Donadeu FX. Characterization of microRNAs differentially expressed during bovine follicle development. Reprod. 2014; 148:271–83.

41 Dubey R, Malhotra SS, Gupta SK. Forskolin-mediated BeWo cell fusion involves down-regulation of miR-92a-1-5p that targets dysferlin and protein kinase CAMP-activated catalytic subunit alpha. Am J Reprod Immunol. 2018; 79:e12834.

42 Michlewski G, Cáceres JF. Post-transcriptional control of miRNA biogenesis. RNA. 2019; 25:1–16.

43 Estella C, Herrer I, Moreno-Moya JM, Quiñonero A, Martínez S, Pellicer A, et al. miRNA signature and Dicer requirement during human endometrial stromal decidualization in vitro. PLoS One. 2012; 7:e41080.

44 Hostrup M, Onslev J, Jacobson GA, Wilson R, Bangsbo J. Chronic β2-adrenoceptor agonist treatment alters muscle proteome and functional adaptations induced by high intensity training in young men. J Physiol. 2018; 596:231–52.